Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more
Toleranzia AB (TOL) - Net Assets
Latest net assets as of June 2025: Skr173.87 Million SEK
Based on the latest financial reports, Toleranzia AB (TOL) has net assets worth Skr173.87 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr183.41 Million) and total liabilities (Skr9.54 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr173.87 Million |
| % of Total Assets | 94.8% |
| Annual Growth Rate | 88.37% |
| 5-Year Change | 165.11% |
| 10-Year Change | 636.46% |
| Growth Volatility | 403.7 |
Toleranzia AB - Net Assets Trend (2012–2024)
This chart illustrates how Toleranzia AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Toleranzia AB (2012–2024)
The table below shows the annual net assets of Toleranzia AB from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr180.07 Million | +17.30% |
| 2023-12-31 | Skr153.52 Million | +28.46% |
| 2022-12-31 | Skr119.51 Million | -6.61% |
| 2021-12-31 | Skr127.97 Million | +88.40% |
| 2020-12-31 | Skr67.92 Million | +94.14% |
| 2019-12-31 | Skr34.99 Million | +26.83% |
| 2018-12-31 | Skr27.59 Million | +88.08% |
| 2017-12-31 | Skr14.67 Million | -26.88% |
| 2016-12-31 | Skr20.06 Million | -17.96% |
| 2015-12-31 | Skr24.45 Million | +1323.29% |
| 2014-12-31 | Skr1.72 Million | +101.60% |
| 2013-12-31 | Skr852.15K | +844.78% |
| 2012-12-31 | Skr90.20K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Toleranzia AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 581508.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr33.87 Million | 18.81% |
| Other Comprehensive Income | Skr168.76 Million | 93.72% |
| Other Components | Skr211.15 Million | 117.26% |
| Total Equity | Skr180.07 Million | 100.00% |
Toleranzia AB Competitors by Market Cap
The table below lists competitors of Toleranzia AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chih Lien Industrial Co Ltd
TW:2024
|
$9.14 Million |
|
PT Primadaya Plastisindo Tbk
JK:PDPP
|
$9.15 Million |
|
Container Store Group Inc
NYSE:TCS
|
$9.15 Million |
|
Thomas Scott (India) Limited
NSE:THOMASCOTT
|
$9.15 Million |
|
Dycasa SA
BA:DYCA
|
$9.14 Million |
|
Maritime Resources Corp
PINK:MRTMF
|
$9.14 Million |
|
Maoye International Holdings Limited
F:5MIA
|
$9.13 Million |
|
Kavveri Telecom Products Limited
NSE:KAVVERITEL
|
$9.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Toleranzia AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 153,518,000 to 180,074,000, a change of 26,556,000 (17.3%).
- Net loss of 9,436,000 reduced equity.
- New share issuances of 36,946,000 increased equity.
- Other comprehensive income increased equity by 29,938,000.
- Other factors decreased equity by 30,892,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-9.44 Million | -5.24% |
| Share Issuances | Skr36.95 Million | +20.52% |
| Other Comprehensive Income | Skr29.94 Million | +16.63% |
| Other Changes | Skr-30.89 Million | -17.16% |
| Total Change | Skr- | 17.30% |
Book Value vs Market Value Analysis
This analysis compares Toleranzia AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 16.98x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | Skr0.03 | Skr0.48 | x |
| 2013-12-31 | Skr0.27 | Skr0.48 | x |
| 2014-12-31 | Skr0.15 | Skr0.48 | x |
| 2015-12-31 | Skr2.21 | Skr0.48 | x |
| 2016-12-31 | Skr1.82 | Skr0.48 | x |
| 2017-12-31 | Skr1.51 | Skr0.48 | x |
| 2018-12-31 | Skr1.93 | Skr0.48 | x |
| 2019-12-31 | Skr1.80 | Skr0.48 | x |
| 2020-12-31 | Skr1.25 | Skr0.48 | x |
| 2021-12-31 | Skr1.82 | Skr0.48 | x |
| 2022-12-31 | Skr1.08 | Skr0.48 | x |
| 2023-12-31 | Skr1.15 | Skr0.48 | x |
| 2024-12-31 | Skr0.85 | Skr0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Toleranzia AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.24%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -31.43%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.04x
- Recent ROE (-5.24%) is above the historical average (-11.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 44.57% | 0.65% | 3.28x | 21.05x | Skr31.18K |
| 2013 | 4.57% | 1.23% | 1.75x | 2.12x | Skr-46.26K |
| 2014 | -42.91% | -238.58% | 0.10x | 1.83x | Skr-909.02K |
| 2015 | -16.81% | -6225.87% | 0.00x | 1.11x | Skr-6.55 Million |
| 2016 | -25.20% | -139.23% | 0.16x | 1.11x | Skr-7.06 Million |
| 2017 | -36.76% | -212.93% | 0.15x | 1.14x | Skr-6.86 Million |
| 2018 | -20.51% | -132.26% | 0.14x | 1.10x | Skr-8.42 Million |
| 2019 | -28.38% | -142.88% | 0.18x | 1.10x | Skr-13.43 Million |
| 2020 | -7.21% | -38.00% | 0.18x | 1.07x | Skr-11.69 Million |
| 2021 | -4.91% | -22.78% | 0.21x | 1.03x | Skr-19.08 Million |
| 2022 | -7.08% | -23.91% | 0.28x | 1.05x | Skr-20.41 Million |
| 2023 | -4.86% | -14.65% | 0.32x | 1.05x | Skr-22.81 Million |
| 2024 | -5.24% | -31.43% | 0.16x | 1.04x | Skr-27.44 Million |
Industry Comparison
This section compares Toleranzia AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $94,923,042
- Average return on equity (ROE) among peers: -56.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Toleranzia AB (TOL) | Skr173.87 Million | 44.57% | 0.05x | $9.14 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $15.08 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |